Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome

Bundeff, Andrew W.; Woodis, C. B.

doi:10.1177/1060028014528151

Cited by 33 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This meta-analysis indicated that TCAs could improve global symptoms, but SSRIs showed no statistically significant difference when compared with the control groups. The results were consistent with a systematic review that was recently published by Bundeff and Woodis [ 21 ] who believed the data evaluating the use of SSRIs in the treatment of IBS were conflicting. They advised that SSRIs should not be routinely used to treat IBS in those patients without comorbid psychiatric conditions [ 21 ].…”

Section: Discussionsupporting

confidence: 91%

Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

AimThe aim of this meta-analysis was to analyze the efficacy and safety of antidepressants for the treatment of irritable bowel syndrome.MethodsWe searched MEDLINE, EMBASE, Scopus and The Cochrane Library for randomized controlled trials investigating the efficacy and safety of antidepressants in the treatment of irritable bowel syndrome. Article quality was evaluated by Jadad score. RevMan 5.0 and Stata 12.0 were used for the meta-analysis.ResultsTwelve randomized controlled trials were included in this study and most of these trials were of high quality (Jadad score ≥4). Five articles focused on tricyclic antidepressants, six articles involved selective serotonin reuptake inhibitors, and one article investigated both types of treatment. The pooled risk ratio showed antidepressant treatment can improve global symptoms (RR = 1.38, 95% CI 1.08, 1.77). In the subgroup analysis, treatment with tricyclic antidepressants showed an improvement in global symptoms (RR = 1.36, 95% CI 1.07, 1.71), while treatment with selective serotonin reuptake inhibitors showed no statistically significant difference in global symptoms compared with the control groups (RR = 1.38, 95% CI 0.83, 2.28). The pooled risk ratio of dropout due to side effects following antidepressant treatment was 1.71 with 95% CI (0.98, 2.99). The subgroup analysis showed the pooled risk ratio of dropout in the tricyclic antidepressants group was 1.92 with 95% CI (0.89, 4.17). In the selective serotonin reuptake inhibitors group, the pooled risk ratio of dropout was 1.5 with 95% CI (0.67, 3.37). Selective serotonin reuptake inhibitors showed no benefit in alleviating abdominal pain and improving quality of life. There was no difference in the incidence of common adverse events between treatment and control groups.ConclusionsTCAs can improve global symptoms of irritable bowel syndrome, while there was no strong evidence to confirm the effectiveness of SSRIs for the treatment of IBS.

show abstract

Section: Discussionsupporting

confidence: 91%

Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Since there is no effective cure for IBS, the treatment focuses on alleviating the particular symptoms. New therapeutic options for IBS include tricyclic antidepressants (Rahimi et al, 2009), spasmolytics (Tack et al, 2016), selective serotonin reuptake inhibitors (Bundeff and Woodis, 2014), lubiprostone (Chang et al, 2016) and linaclotide (Chey et al, 2011), and 5hydroxytryptamine type-3 antagonists such as ramosetron and alosetron (Andresen et al, 2008). However, current treatments are not very useful or may cause adverse reactions (Trinkley and Nahata, 2014).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Li²,

Deng³

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In their review, Bundeff and Woodies have illustrated that fluoxetine, citalopram and paroxetine are useful for the treatment of irritable bowel syndrome, but the available data evaluating these agents are conflicting [25] . The same conclusion was drawn for atypical antipsychotics [26] .…”

Section: Dimensional Psychopharmacology Approach To Somatic Symptom Dmentioning

confidence: 97%

Dimensional Psychopharmacology in Somatising Patients

Biondi

Pasquini

2015

Clinical Challenges in the Biopsychosocial Interface

View full text Add to dashboard Cite

Despite the recent DSM-5 review of somatoform disorders, which are now called somatic symptom and related disorders, the categorical definitions of these syndromes have inherent limitations because their causal mechanism or presumed aetiologies are still unknown. These limitations may affect everyday clinical practice and decision-making abilities. As a result, physicians have limited information at their disposal to treat these patients. Furthermore, the clinical presentations of somatic disorders may vary a lot. The purpose of this chapter is to illustrate a psychopathological dimensional approach to the somatising patient. This approach is constantly unconsciously applied in clinical practice using continuous variables, such as rating scales. Moreover, treatment strategies might be improved by adding a dimensional approach, simply recognising the prominent components of the presenting psychopathology of a given patient and addressing them with drugs according to their different mechanisms, targeting circuits and neurotransmitters. Some authors have proposed a shift from the nosological to functional application of psychotropic drugs, in which functional psychopharmacology will be dysfunction oriented and therefore inevitably geared towards utilising drug combinations. Here, we present a summary of the advantages of functional/dimensional psychopharmacology for the treatment of somatic symptoms and related disorders.

show abstract

Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome

Abstract: Available data evaluating the use of SSRIs in the treatment of IBS-related symptoms are conflicting. Additional larger RCTs lasting more than 12 weeks are needed to determine the place in therapy for SSRIs in the treatment of IBS-related symptoms.

Cited by 33 publications

References 18 publications

Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis

Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis

Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

Dimensional Psychopharmacology in Somatising Patients

Contact Info

Product

Resources

About